(Q40689148)

English

Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis

scientific article published on 3 May 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Eiichi Ogawa

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Norihiro Furusyo

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Naoki Yamashita

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Akira Kawano

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kazuhiro Takahashi

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kazufumi Dohmen

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Makoto Nakamuta

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Takeaki Satoh

8

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Hideyuki Nomura

9

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Koichi Azuma

10

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Toshimasa Koyanagi

11

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kazuhiro Kotoh

12

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Shinji Shimoda

13

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Eiji Kajiwara

14

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Jun Hayashi

15

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kyushu University Liver Disease Study(KULDS) Group

16

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

3 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

E120-E131

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Epidemiology of hepatitis C virus in japan

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Health-State Utilities and Quality of Life in Hepatitis C Patients

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12738

21 January 2018

Identifiers

10.1111/HEPR.12738

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

release_wc4uo3ny2vdofcw3swkes555di

1 reference

https://api.fatcat.wiki/v0/release/wc4uo3ny2vdofcw3swkes555di

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40689148&oldid=1904835432"